Moreover, these EVs have demonstrated significant tumor growth inhibition and extended survival in multiple preclinical tumor models, including melanoma, liver cancer, and breast cancer, outperforming anti-DR5 antibodies. This evidence concerns the gene TNFRSF10B and liver cancer.